84624-27-1

Basic information

• Product Name: N-Boc-N'-Fmoc-L-Lysine
• Synonyms: N-α-Boc-N-ε-Fmoc-L-lysine;N(ALPHA)-BOC-N(EPSILON)-FMOC-L-LYSINE 98+%;N-t-BOC-N-U-FMOC-L-lysine;BOC-L-LYS(FROM)-OH;N-ALPHA-T-BUTYLOXYCARBONYL-N-EPSILON-(9-FLUORENYLMETHYLOXYCARBONYL)-L-LYSINE;NALPHA-tert-Butoxycarbonyl-NEPSILON-9-fluorenylmethoxycarbonyl-L- lysine;6-(9H-Fluoren-9-ylmethoxycarbonylamino)-2-(tert-butoxycarbonylamino)hexanoic acid;BOC-N-E-FMOC-L-LYSINE
• CAS NO: 84624-27-1
• Molecular Formula: C₂₆H₃₂N₂O₆
• Molecular Weight: 468.54
• Product Categories: Amino Acids;Lysine [Lys, K];Boc-Amino Acids and Derivative;Boc-Amino acid series
• Mol File: 84624-27-1.mol

Chemical Properties

• Melting Point: 93-98℃
• Boiling Point: 685.7 °C at 760 mmHg
• Flash Point: 368.5 °C
• Appearance: White/Solid
• Density: 1.21 g/cm³
• Vapor Pressure: 9.55E-20mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: 2-8°C
• PKA: 3.99±0.21(Predicted)
• Water Solubility: Soluble in dimethylformamide. Insoluble in water.
• CAS DataBase Reference: N-Boc-N'-Fmoc-L-Lysine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-N'-Fmoc-L-Lysine(84624-27-1)
• EPA Substance Registry System: N-Boc-N'-Fmoc-L-Lysine(84624-27-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 84624-27-1(Hazardous Substances Data)

Usage

Uses

Nalpha-Boc-Nepsilon-Fmoc-L-lysine is used as a pharmaceutical intermediate.

General Description

The product number for this product was previously 04-12-0069.To obtain a certificate of analysis (CoA) of a lot that begins with the letter “A”, please select the option in the right hand menu “Request a COA for Lot#s starting with A”.

InChI:InChI=1/C26H32N2O6/c1-26(2,3)34-25(32)28-22(23(29)30)14-8-9-15-27-24(31)33-16-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,21-22H,8-9,14-16H2,1-3H3,(H,27,31)(H,28,32)(H,29,30)

Upstream product

• 80994-44-1 {[(tert-butoxycarbonyl)oxy]amino}(phenyl)acetonitrile 
• 84624-28-2 N-(fluorenyl-9-methoxycarbonyl)-L-lysine 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 13734-28-6 Boc-Lys-OH 
• 657-27-2 L-Lysine hydrochloride 
• 28920-44-7 (9H-fluoren-9-yl)methyl azidoformate 
• 133628-28-1 N-α-Boc-N-ε-Fmoc-L-lysine methyl ester 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 39691-88-8 [Cu(L-LysO)2] 

Downstream Products

• 1020727-14-3 C₅₈H₉₆N₁₄O₈ 
• 1020727-15-4 C₅₇H₈₅N₁₅O₇ 
• 1020727-17-6 C₅₃H₇₇N₁₅O₇ 
• 1020727-18-7 C₅₃H₇₇N₁₅O₇ 
• 1020727-19-8 C₄₇H₇₆N₁₄O₇ 
• 1020727-22-3 C₆₉H₁₀₃N₂₅O₉ 
• 1417911-59-1 cyclo(β³-HLys(Fmoc)-β³-HLys(N₃)-β³-HLys(Cbz)) 
• 1417911-63-7 cyclo(β³-HLys(Fmoc)-β³-HLys(N₃)-β³-HLys((N4-benzyloxycarbonyl)cytosine-1-yl acetate)) 
• 1417911-64-8 cyclo(β³-HLysNH₂-β³-HLys(N₃)-β³-HLys((N4-benzyloxycarbonyl)cytosine-1-yl acetate)) 
• 134653-30-8 Boc-Ada⁴(Bzl₂) p-nitrobenzyl ester 
• 134653-42-2 Boc-Ada⁴(Bzl₂) 
• 96561-04-5 (S)-6-trifluoroacetylamino-2-(tert-butoxycarbonylamino)-hexanoic acid 

Relevant articles and documents

CHEMICAL PROBES AND METHODS OF USE THEREOF

Provided herein are turn-on fluorescent chemical probes useful for monitoring and/or detecting lysine delipoylation activity in a sample including or suspected of including a delipoylation enzyme.

Chemical Probes Reveal Sirt2's New Function as a Robust "eraser" of Lysine Lipoylation

Lysine lipoylation, a highly conserved lysine post-translational modification, plays a critical role in regulating cell metabolism. The catalytic activity of a number of vital metabolic proteins, such as pyruvate dehydrogenase (PDH), depends on lysine lipoylation. Despite its important roles, the detailed biological regulatory mechanism of lysine lipoylation remains largely unexplored. Herein we designed a powerful affinity-based probe, KPlip, to interrogate the interactions of lipoylated peptide/proteins under native cellular environment. Large-scale chemical proteomics analysis revealed a number of binding proteins of KPlip, including sirtuin 2 (Sirt2), an NAD+-dependent protein deacylase. To explore the potential activity of Sirt2 toward lysine lipoylation, we designed a single-step fluorogenic probe, KTlip, which reports delipoylation activity in a continuous manner. The results showed that Sirt2 led to significant delipoylation of KTlip, displaying up to a 60-fold fluorescence increase in the assay. Further kinetic experiments with different peptide substrates revealed that Sirt2 can catalyze the delipoylation of peptide (DLAT-PDH, K259) with a remarkable catalytic efficiency (kcat/Km) of 3.26 × 103 s-1 M-1. The activity is about 400-fold higher than that of Sirt4, the only mammalian enzyme with known delipoylation activity. Furthermore, overexpression and silencing experiments demonstrated that Sirt2 regulates the lipoylation level and the activity of endogenous PDH, thus unequivocally confirming that PDH is a genuine physiological substrate of Sirt2. Using our chemical probes, we have successfully established the relationship between Sirt2 and lysine lipoylation in living cells for the first time. We envision that such chemical probes will serve as useful tools for delineating the roles of lysine lipoylation in biology and diseases.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS

Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.

BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.